All-cause and incremental per patient per year cost associated with chronic hepatitis C virus and associated liver complications in the United States: a managed care perspective.
about
Burden of disease and cost of chronic hepatitis C infection in CanadaOutcomes and management of viral hepatitis and human immunodeficiency virus co-infection in liver transplantationCost-effectiveness of Telaprevir combination therapy for chronic hepatitis CFactors associated with success of telaprevir- and boceprevir-based triple therapy for hepatitis C virus infection.The hepatitis C cascade of care: identifying priorities to improve clinical outcomesCost-effectiveness of hepatitis C treatment using generic direct-acting antivirals available in IndiaThe cost-effectiveness of improved hepatitis C virus therapies in HIV/hepatitis C virus coinfected patients.Costs of telaprevir-based triple therapy for hepatitis C: $189,000 per sustained virological responseThe economic burden of advanced liver disease among patients with hepatitis C virus: a large state Medicaid perspectiveBoceprevir for previously untreated patients with chronic hepatitis C Genotype 1 infection: a US-based cost-effectiveness modeling studyAchieving sustained virologic response in hepatitis C: a systematic review of the clinical, economic and quality of life benefitsCurrent practices of screening for incident hepatitis C virus (HCV) infection among HIV-infected, HCV-uninfected individuals in primary care.Ascertainment and verification of end-stage renal disease and end-stage liver disease in the north american AIDS cohort collaboration on research and designThe cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection.Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United StatesHepatitis C in the era of direct-acting antivirals: real-world costs of untreated chronic hepatitis C; a cross-sectional studyHepatitis C virus therapy is associated with lower health care costs not only in noncirrhotic patients but also in patients with end-stage liver disease.Pricey pills for an even pricier problem.Economic and Public Health Impacts of Policies Restricting Access to Hepatitis C Treatment for Medicaid Patients.Economic burden of hepatitis B infection among patients with diabetes.Chronic hepatitis C virus (HCV) disease burden and cost in the United States.Cost-effectiveness of boceprevir in patients previously treated for chronic hepatitis C genotype 1 infection in the United States.Disease progression and health care resource consumption in patients affected by hepatitis C virus in real practice setting.The new paradigm of hepatitis C therapy: integration of oral therapies into best practices.Cost-effectiveness of Early Treatment of Hepatitis C Virus Genotype 1 by Stage of Liver Fibrosis in a US Treatment-Naive Population.Healthcare Costs Related to Treatment of Hepatocellular Carcinoma Among Veterans With Cirrhosis in the United States.Chronic Hepatitis C-Related Cirrhosis Hospitalization Cost Analysis in Bulgaria.Healthcare Costs for Chronic Hepatitis C in South Korea from 2009 to 2013: An Analysis of the National Health Insurance Claims' Data.Health and economic benefits of reducing sugar intake in the USA, including effects via non-alcoholic fatty liver disease: a microsimulation model.Cost Effectiveness of Pre- vs Post-Liver Transplant Hepatitis C Treatment With Direct-Acting Antivirals.Assessment of cost of innovation versus the value of health gains associated with treatment of chronic hepatitis C in the United States: The quality-adjusted cost of care.The Potential Return on Public Investment in Detecting Adverse Drug Effects.Long-term disease and economic outcomes of prior authorization criteria for Hepatitis C treatment in Pennsylvania Medicaid.Prevalence of cirrhosis in hepatitis C patients in the Chronic Hepatitis Cohort Study (CHeCS): a retrospective and prospective observational study.Deaths among people with hepatitis C in New York City, 2000-2011.Should we treat acute hepatitis C? A decision and cost-effectiveness analysis.Prevalence and economic burden of extrahepatic manifestations of hepatitis C virus are underestimated but can be improved with therapy.Newly Diagnosed Hepatitis C in the US Commercially Insured Population Before and After the 2012 Implementation of Expanded Screening Guidelines.Cost-Effectiveness of Treatments for Genotype 1 Hepatitis C Virus Infection in non-VA and VA Populations.
P2860
Q26849591-A87089E0-B0AE-4495-8BB7-21542B0A048EQ26864478-BAC5B500-3FFD-40BE-8A0B-084BED176555Q28540562-2AF1CA3E-F209-4436-B236-BE901C193E64Q33576531-F4F524FF-C7B8-4956-B50A-B11AE9FAC897Q33632459-FD949B9F-E506-4C67-9051-7970C24E1090Q33698956-6DDD53AA-DB9B-4C6A-998A-775A2D6808CDQ33710740-84EBD881-FAF2-40BA-A957-23807C6261FEQ34310417-5088D8BB-3DE9-40A9-9C1F-8FF4850BE81FQ34512967-09A297F5-F631-41E4-B9FD-1072EAFD2F11Q34690368-19C477FC-CF52-456D-9B27-A44E2FBB5536Q34987336-0BB40DCE-D2DC-4141-BA7E-699858E707FCQ35029328-D2EA9AD3-DEC0-4D08-B3B6-828197ECCF24Q35150425-75B95F6B-F652-417B-A30D-DAD2830764C0Q35572125-99796451-05AB-469D-A161-2BAA185837C3Q35619161-84A71F62-FBAE-4A7B-A1D0-E31B062C7EA2Q35822155-E3914B5C-2BA1-4ADC-A4EC-8FD835B10919Q36006326-6F30CBDC-AEA0-4326-B47A-FFFC2CD36705Q36751083-0F5FF2A4-A978-47B3-9CE3-903A7B62536DQ37027342-09650B8F-4659-479D-A0DC-4BB9792A670BQ37131065-7EBC8A5F-832D-4190-B2EA-598698F043DAQ37148328-BA557148-8B21-4E13-A0A9-1B7881C44F09Q37286544-D50B0049-1B31-49A0-9973-73EB649016D3Q37354282-2B6722FD-5EAC-48E3-8596-81EA8DCB696EQ37455611-119CC5E2-71C8-4E31-BE6B-9F098AE1898CQ37484155-B6551074-068B-4DAB-8C8C-D032F3C6E964Q38399579-A798B2B3-0C1A-41A0-91D7-E045AFEF5C9DQ38616536-6F83FAA1-742D-4B0C-8CE8-34593B1EA370Q38629751-9E3F469B-4F2C-49E7-9426-4EA5D67A176AQ38642356-48626F7E-D385-4800-8EE2-0D0D3592907FQ38716554-EFE7FB85-6BF5-4742-9509-AFC1C5AA6599Q38980602-4AC53859-F6A8-4138-A970-A73CE93843B0Q40201233-4ACF31FB-9402-40E4-B533-E1D6D0E03FBFQ40417472-F4D81B3C-EE8B-404D-A4D9-8B9CDD3E49A5Q40690948-11B0C881-DDAB-404F-B0C7-E4972C5FC186Q42237379-BB52E9E6-02B8-41B5-8797-B3D02DB481B7Q47603693-ECA42F76-460A-4C3C-8C00-83DBCC9B5AA4Q51366504-2629637A-BA25-4D6B-8C44-58267CC46C39Q52564579-CC9A2844-6DAD-4258-9A3D-D51C778FBA3AQ54984374-BFE50206-4334-4085-86AA-DF2FBBD38B2C
P2860
All-cause and incremental per patient per year cost associated with chronic hepatitis C virus and associated liver complications in the United States: a managed care perspective.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
All-cause and incremental per ...... s: a managed care perspective.
@en
All-cause and incremental per ...... s: a managed care perspective.
@nl
type
label
All-cause and incremental per ...... s: a managed care perspective.
@en
All-cause and incremental per ...... s: a managed care perspective.
@nl
prefLabel
All-cause and incremental per ...... s: a managed care perspective.
@en
All-cause and incremental per ...... s: a managed care perspective.
@nl
P2093
P1476
All-cause and incremental per ...... s: a managed care perspective.
@en
P2093
Baris Deniz
Carrie McAdam-Marx
Christopher A Hane
Diana I Brixner
Joseph Biskupiak
P304
P356
10.18553/JMCP.2011.17.7.531
P577
2011-09-01T00:00:00Z